RedHill Biopharma (RDHL) Free Cash Flow (2016 - 2022)

RedHill Biopharma has reported Free Cash Flow over the past 11 years, most recently at -$2.4 million for Q4 2022.

  • Quarterly Free Cash Flow rose 83.7% to -$2.4 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$2.4 million through Dec 2023, up 91.65% year-over-year, with the annual reading at -$7.2 million for FY2025, 19.49% up from the prior year.
  • Free Cash Flow was -$2.4 million for Q4 2022 at RedHill Biopharma, up from -$6.0 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at -$2.4 million in Q4 2022 and troughed at -$19.0 million in Q3 2021.
  • The 5-year median for Free Cash Flow is -$9.9 million (2018), against an average of -$10.8 million.
  • Year-over-year, Free Cash Flow tumbled 111.04% in 2021 and then soared 83.7% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$8.2 million in 2018, then plummeted by 68.96% to -$13.8 million in 2019, then rose by 8.53% to -$12.7 million in 2020, then fell by 17.38% to -$14.9 million in 2021, then soared by 83.7% to -$2.4 million in 2022.
  • Per Business Quant, the three most recent readings for RDHL's Free Cash Flow are -$2.4 million (Q4 2022), -$6.0 million (Q3 2022), and -$16.4 million (Q2 2022).